

## Brief Biography



Name	Jae-ho, Yoon, MD, PhD
Major	Department of Hematology, Leukemia center

<b>학력 및 자격사항</b>	2003 가톨릭대학교 의과대학 의학사 2008 내과 전문의 취득 2016 가톨릭대학교 의과대학 의학박사
<b>경력 및 연수</b>	2003. 3. – 2008. 2. 가톨릭중앙의료원 내과 인턴/전공의 2011. 5. – 2014. 2. 가톨릭대학교 서울성모병원 혈액내과 전임의 2014. 3. – 2020. 3. 가톨릭대학교 서울성모병원 혈액내과 임상조교수/조교수 2021. 2. – 2022. 1. 미국 Memorial Sloan Kettering Cancer Center, Visiting investigator 2022. 2. – 2022. 7. 캐나다 University of Ottawa Department of BMI, Visiting investigator 2020. 4. – 현재 가톨릭대학교 서울성모병원 혈액내과 부교수
<b>수상경력</b>	2012 제53회 대한혈액학회 우수연제학술상 2013 제18회 대한조혈모세포이식학회 우수연제학술상 2015 대한내과학회 – 우수논문상 2017 대한혈액학회 – 우수연구자상 2018 대한조혈모세포이식학회 – 우수논문상 2020 대학혈액학회 – 우수연구자상 2022 대한조혈모세포이식학회 – 우수구연상
<b>학회활동</b>	현 대한내과학회 정회원 현 대한혈액학회 정회원 현 대한조혈모세포이식학회 정회원 현 미국혈액학회 정회원  2015~현재: 대한혈액학회 성인림프구성백혈병연구회, 조직구증식증연구회 학술위원 대한혈액학회 조직구질환연구회 위원
<b>대표논문</b>	<b>Yoon JH</b> , Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis. Therapeutic advances in hematology. 2023;14:20406207231154713. <b>Yoon JH</b> , Kim HS, Min GJ, Park SS, Park S, Lee SE, et al. Cytogenetic and molecular characteristics and outcomes of adult patients with early T-cell precursor acute lymphoblastic leukemia. Eur J Haematol. 2023;110(2):137-48.

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. *Therapeutic advances in hematology*. 2022;13:  
Lee SH, **Yoon JH (Co-first author)**, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. *Int J Hematol*. 2022;115(1):135-9.

Lee S, **Yoon JH (Correspondence)**, Lee E, Park SS, Park MS, Jung J, Min GJ, et al. Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2022.

Kwag D, **Yoon JH (Correspondence)**, Min GJ, Park SS, Park S, Lee SE, et al. Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response. *Acta Haematol*. 2022.

Lee J, **Yoon JH (Co-first author)**, Kwag D, Lee JH, Kim TY, Min GJ, et al. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. *Therapeutic advances in hematology*. 2021;12:20406207211066176.

Cho H, Kim Y, **Yoon JH (Co-first author)**, Lee J, Lee GD, Son J, et al. Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. *Bone Marrow Transplant*. 2021.

**Yoon JH**, Choi CW, Won JH. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. *The Korean journal of internal medicine*. 2021.

Oh EJ, **Yoon JH (Correspondence)**, Park KH, Bae HJ, Yun SJ, Min GJ, et al. Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study. *Therapeutic advances in hematology*. 2021;12:20406207211020544.

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al*. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. *Bone Marrow Transplant* 2021. e-pub ahead of print 2021/02/03; doi: 10.1038/s41409-021-01215-y

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al*. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant* 2021; **56**(4): 828-840. e-pub ahead of print 2020/11/01; doi: 10.1038/s41409-020-01097-6

**Yoon JH**, Park SS, Min GJ, Park S, Lee SE, Cho BS *et al*. Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. *Therapeutic advances in hematology* 2020; **11**: 2040620720932038

Yoon SY, **Yoon JH (Co-first)**, Min GJ, Park SS, Park S, Lee SE *et al*. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2020; **55**(7): 1469-1472

**Yoon JH**, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al*. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer medicine* 2019. doi: 10.1002/cam4.2680

**Yoon JH**, Kim HJ, Min GJ, Park SS, Jeon YW, Lee SE, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. *Scientific reports*. 2019;9(1):11935.

**Yoon JH**, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning

for adult Philadelphia-positive acute lymphoblastic leukemia. *Cancer*. 2019;125(6):873-83.

**Yoon JH**, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. *Bone Marrow Transplant*. 2019;54(2):330-3.

**Yoon JH**, Park SS, Jeon YW, Lee SE, Cho BS, Eom KS, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. *Haematologica*. 2019;104(2):269-76.

**Yoon JH**, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). *Bone Marrow Transplant*. 2019;54(8):1361-8.

**Yoon JH** et al. The effects of early intensified induction chemotherapy in adult patients with acute myeloid leukemia compared to standard 3+7 chemotherapy. *Blood res* 2017

**Yoon JH** et al. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation? *Biol Blood Marrow Transplant*. 2017.

**Yoon JH** et al. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. *Oncotarget*. 2017.

Park SS, **Yoon JH (Co-first)** et al. Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2017;17(1):38-45 e2.

**Yoon JH** et al. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RAR $\alpha$  after anthracycline-based chemotherapy: a single-center cohort study. *J Hematol Oncol*. 2017;10(1):30.

**Yoon JH** et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. *Ann Oncol*. 2016.

**Yoon JH** et al. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. *Oncotarget*. 2016.

**Yoon JH** et al. Role of the frontline autologous stem cell transplantation for high-risk young DLBCL patients who showed sensitivity to R-CHOP: Retrospective comparative analysis with a well-matched risk group treated with R-CHOP alone. *Korean J Intern Med*. 2015

**Yoon JH** et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. *Genes Chromosomes Cancer*. 2015.

**Yoon JH** et al. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. *Hematol Oncol*. 2015.

**Yoon JH** et al. Wilms Tumor Gene 1 Expression as a Predictive Marker for Relapse and Survival after Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 2015.

**Yoon JH** et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. *Bone Marrow Transplant*. 2014;49(12):1466-74.

**Yoon JH** et al. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2014

**Yoon JH** et al. Stratification of de novo adult AML with adverse-risk karyotype: Can we overcome the worse prognosis of adverse-risk group AML with hematopoietic stem cell transplantation? *Biol Blood Marrow Transplant* 2014.

**Yoon JH** et al. Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence. Hematol Oncol 2014.

**Yoon JH** et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. Am J Hematol. 2013;88(12):1074-81.

**Yoon JH** et al. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Bone Marrow Transplant 2013.

**Yoon JH** et al. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Leuk Lymphoma 2013.

**Yoon JH** et al. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia. Biol Blood Marrow Transplant 2013;19:958-966.

**Yoon JH** et al. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol 2013;91:112-121.